R&D News | pharmaphorum

News

AbbVie inks $713m deal for OSE chronic inflammation drug

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Im

News

David Campbell, founder, president and CEO of Janux

Janux plans $200m offer on back of prostate cancer readout

Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stoc

News

University of Southampton scientist Prof Ali Tavassoli, who is Curve's chief scientific officer

UK biotech Curve swings £40.5m in Pfizer-backed round

Southampton, UK-based start-up Curve Therapeutics has completed a £40.5 million ($51 million) in Series A financing for its drug discovery platform that enables drug scree

News

Novo Nordisk joins molecular glue club with Neomorph deal

Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph t

News

Boehringer’s survodutide shows monster MASH potential

Boehringer Ingelheim’s weight-loss drug candidate survodutide could also be effective for liver disease metabolic dysfunction-associated steatohepatitis (MASH), if the res

News

GSK antibiotic gepotidacin clears phase 3 gonorrhoea trial

GSK has reported topline results from a phase 3 trial of its novel antibiotic gepotidacin that could spell the end of a decades-long drought in new oral therapies for gonorrhoea.

AbbVie inks $713m deal for OSE chronic inflammation drug

Janux plans $200m offer on back of prostate cancer readout

UK biotech Curve swings £40.5m in Pfizer-backed round

Novo Nordisk joins molecular glue club with Neomorph deal

Boehringer’s survodutide shows monster MASH potential

GSK antibiotic gepotidacin clears phase 3 gonorrhoea trial

FDA declines to approve AbbVie's Botox follow-up

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks